Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$2.37 USD
-0.09 (-3.66%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.31 -0.06 (-2.53%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for Moleculin Biotech, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 31 | 23 | 20 | 18 |
Income After Depreciation & Amortization | -30 | -31 | -23 | -20 | -18 |
Non-Operating Income | 0 | 2 | 7 | 2 | 4 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -30 | -29 | -16 | -17 | -13 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -29 | -16 | -17 | -13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -29 | -16 | -17 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -30 | -31 | -23 | -20 | -17 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -30 | -31 | -23 | -20 | -18 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.98 | 1.91 | 1.79 | 0.66 | 0.45 |
Diluted EPS Before Non-Recurring Items | -15.07 | -15.14 | -12.59 | -26.39 | -28.78 |
Diluted Net EPS (GAAP) | -225.94 | -15.14 | -8.85 | -26.39 | -28.78 |
Fiscal Year end for Moleculin Biotech, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 6.18 | 6.67 | 8.91 | 5.95 | 6.41 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.18 | -6.67 | -8.91 | -5.95 | -6.41 |
Non-Operating Income | 1.87 | 1.71 | -1.35 | 0.34 | 0.44 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -4.32 | -4.97 | -10.27 | -5.61 | -5.98 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.32 | -4.97 | -10.27 | -5.61 | -5.98 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.32 | -4.97 | -10.27 | -5.61 | -5.98 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 2.54 | 2.47 | NA | 1.99 | 1.98 |
Diluted EPS Before Non-Recurring Items | -2.23 | -2.02 | NA | -2.85 | -3.00 |
Diluted Net EPS (GAAP) | -1.70 | -2.02 | -215.89 | -2.85 | -3.00 |